{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T13:13:24Z","timestamp":1762521204358},"reference-count":38,"publisher":"Wiley","issue":"6a","license":[{"start":{"date-parts":[[2008,6,28]],"date-time":"2008-06-28T00:00:00Z","timestamp":1214611200000},"content-version":"vor","delay-in-days":27,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Internal Medicine Journal"],"published-print":{"date-parts":[[2008,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p><jats:bold>Background:\u2002<\/jats:bold> International data suggest that suboptimal use of allopurinol is common. Allopurinol dose should be lower in renal impairment, but higher when gout is not controlled. The aim of the study was to examine trends in the usage of allopurinol in the Australian community.<\/jats:p><jats:p><jats:bold>Methods:\u2002<\/jats:bold> Community dispensing data on the urate\u2010lowering drugs allopurinol and probenecid were obtained from databases kept by Medicare Australia and the Drug Utilization Sub\u2010Committee, for January 1992 to December 2005.<\/jats:p><jats:p><jats:bold>Results:\u2002<\/jats:bold> Allopurinol comprised 98.4% of all prescriptions for urate\u2010lowering drugs dispensed during 2005. Most prescriptions were for allopurinol 300\u2003mg, but there was a steady shift towards use of allopurinol 100\u2003mg in all states and territories over the period of the study. There were marked variations in prescribing rates across the country. New South Wales had the highest rate of subsidized prescribing for allopurinol 300\u2003mg (39.3 per 1000 population). Tasmania had the highest rate for allopurinol 100\u2003mg (14.3 per 1000 population), which coincided with an educational programme to decrease allopurinol dose in patients with renal impairment. Prescribing rates in the Northern Territory were substantially lower than all other regions, at 10.8 and 3.3 prescriptions per 1000 population for allopurinol 300 and 100\u2003mg, respectively.<\/jats:p><jats:p><jats:bold>Conclusion:\u2002\n\t\t\t\t\t<\/jats:bold> The increased uptake of allopurinol 100\u2003mg suggests greater adherence to dosing guidelines and that there is value in educational programmes to optimize drug usage. Variability in utilization rates across regions indicates the need for research on factors responsible. Precise understanding of dosing trends requires access to deidentified, individual dosing data.<\/jats:p>","DOI":"10.1111\/j.1445-5994.2008.01641.x","type":"journal-article","created":{"date-parts":[[2008,4,17]],"date-time":"2008-04-17T02:43:40Z","timestamp":1208400220000},"page":"388-395","update-policy":"http:\/\/dx.doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Utilization of allopurinol in the Australian community"],"prefix":"10.1111","volume":"38","author":[{"given":"Y.","family":"Chung","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C. Y.","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G. G.","family":"Graham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Mant","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R. O.","family":"Day","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2008,6,28]]},"reference":[{"key":"e_1_2_6_2_2","first-page":"2403","article-title":"Epidemiology of gout: is the incidence rising?","volume":"29","author":"Arromdee A","year":"2002","journal-title":"J Rheumatol"},{"key":"e_1_2_6_3_2","first-page":"1582","article-title":"Increasing prevalence of gout and hyperuricemia over 10 years among older adults in a managed care population","volume":"31","author":"Wallace KL","year":"2004","journal-title":"J Rheumatol"},{"key":"e_1_2_6_4_2","first-page":"66","article-title":"Primary gout in Shantou: a clinical and epidemiological study","volume":"116","author":"Zeng Q","year":"2003","journal-title":"Chin Med J (Engl)"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.22014"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp048015"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2005.03.043"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2004.024091"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(84)90743-5"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.4065\/81.7.925"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keh679"},{"key":"e_1_2_6_12_2","unstructured":"Therapeutic Guidelines Ltd.Gout: management[revised Nov 2007]. eTG complete [Internet]. Melbourne:Therapeutic Guidelines Limited 2007 Rheumatology 2007[cited 2007 Dec 16]. Available from URL:http:\/\/www.tg.com.au\/ip\/complete\/"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1988.tb03401.x"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00315424"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0b013e32802106b9"},{"key":"e_1_2_6_16_2","first-page":"2050","article-title":"A survey of current evaluation and treatment of gout","volume":"33","author":"Schlesinger N","year":"2006","journal-title":"J Rheumatol"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1440-1762.2000.00353.x"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.5694\/j.1326-5377.1989.tb128510.x"},{"key":"e_1_2_6_19_2","unstructured":"Medicare Australia.Pharmaceutical Benefits Scheme Statistical Reports for Items 1227N 1940D 2094F 2600W 2601X 2603B 2604C January 1992 to December 2005. [cited 2006 Nov 29]. Available from URL:http:\/\/www.medicareaustralia.gov.au\/statistics\/dyn_pbs\/forms\/pbs_tab1.shtml"},{"key":"e_1_2_6_20_2","unstructured":"Commonwealth Department of Health and Ageing. Schedule of Pharmaceutical Benefits for Approved Pharmacists and Medical Practitioners.2006 Apr[cited 2006 Nov 29]. Available from URL:http:\/\/www.pbs.gov.au\/html\/healthpro\/publication\/view?date=20060401&type=FlashPaper&name=general\u2010schedule"},{"key":"e_1_2_6_21_2","unstructured":"Commonwealth Department of Health and Ageing.Australian Statistics on Medicines2003. [cited Nov 29]. Available from URL:http:\/\/www.health.gov.au\/internet\/wcms\/publishing.nsf\/Content\/pbs\u2010pubs\u2010asm2003\/"},{"key":"e_1_2_6_22_2","author":"World Health Organization","year":"2004","journal-title":"Guidelines for ATC Classification and DDD Assignment"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMcp030733"},{"key":"e_1_2_6_24_2","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1177\/030006058100900615","article-title":"Benzbromarone therapy in hyperuricaemia; comparison with allopurinol and probenecid","volume":"9","author":"Schepers GW","year":"1981","journal-title":"J Int Med Res"},{"key":"e_1_2_6_25_2","volume-title":"Northern Territory by geographic classification \u2013 electronic delivery","author":"Australian Bureau of Statistics (ABS)","year":"2005"},{"key":"e_1_2_6_26_2","unstructured":"Australian Bureau of Statistics (ABS).Population estimates by age and sex New South Wales by geographic classification \u2013 electronic delivery. Canberra: ABS.2005 Jun. ABS Cat. No.: 3235.1.55.001."},{"key":"e_1_2_6_27_2","unstructured":"Australian Bureau of Statistics (ABS).Population estimates by age and sex Tasmania by geographic classification \u2013 electronic delivery. Canberra: ABS.2005 Jun. ABS Cat. No.: 3235.6.55.001."},{"key":"e_1_2_6_28_2","volume-title":"Medicare and Pharmaceutical Benefits Scheme Usage Patterns in the Northern Territory 1993\/94 to 2003\/04","author":"Byron P","year":"2005"},{"key":"e_1_2_6_29_2","unstructured":"Australian Bureau of Statistics (ABS).Regional statistics Northern Territory \u2013 electronic delivery. Canberra: ABS.2006 Dec. ABS Cat. No.: 1362.7."},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.28.2.150"},{"key":"e_1_2_6_31_2","first-page":"965","article-title":"Rheumatic disease in an Australian Aboriginal community in North Queensland, Australia. A WHO\u2010ILAR COPCORD survey","volume":"31","author":"Minaur N","year":"2004","journal-title":"J Rheumatol"},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.5694\/j.1326-5377.1995.tb138436.x"},{"key":"e_1_2_6_33_2","first-page":"627","year":"2007","journal-title":"Australian Medicines Handbook 2007 Drugs for Gout: Allopurinol"},{"key":"e_1_2_6_34_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199602153340707"},{"key":"e_1_2_6_35_2","doi-asserted-by":"publisher","DOI":"10.1177\/106002809302700317"},{"key":"e_1_2_6_36_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0409500102"},{"key":"e_1_2_6_37_2","first-page":"1646","article-title":"Dose adjustment of allopurinol according to creatinine clearance does not provide adequate control of hyperuricemia in patients with gout","volume":"33","author":"Dalbeth N","year":"2006","journal-title":"J Rheumatol"},{"key":"e_1_2_6_38_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.60.10.981"},{"key":"e_1_2_6_39_2","doi-asserted-by":"publisher","DOI":"10.5694\/j.1326-5377.2007.tb00883.x"}],"container-title":["Internal Medicine Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1445-5994.2008.01641.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1445-5994.2008.01641.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,15]],"date-time":"2023-10-15T04:33:14Z","timestamp":1697344394000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1445-5994.2008.01641.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,6]]},"references-count":38,"journal-issue":{"issue":"6a","published-print":{"date-parts":[[2008,6]]}},"alternative-id":["10.1111\/j.1445-5994.2008.01641.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1445-5994.2008.01641.x","archive":["Portico"],"relation":{},"ISSN":["1444-0903","1445-5994"],"issn-type":[{"value":"1444-0903","type":"print"},{"value":"1445-5994","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,6]]},"assertion":[{"value":"2008-06-28","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}